New Stanford research suggests that young people begin using nicotine products like e-cigarettes by trying fruit, mint or candy flavors.
Stanford researchers disprove the idea that legalizing medical marijuana will lead to fewer deaths from opioid overdoses.
Stanford pain researchers say we can curb the prescription opioid crisis, while treating pain, by using a variety of tactics.
A new study has found that opioid-related deaths are highest on the East Coast and opioids are affecting an increasing number of African-Americans.
Experts studying nicotine and e-cigarette norms say that Juul has instigated a "nicotine arms race," causing a shift across the e-cigarette industry.
Alvin Roth, a Nobel laureate and Stanford faculty member, explains how the economic concept of repugnant markets applies to heroin in the United States.
Small trial conducted by Stanford researchers links activity in the brain's reward processing system with drug relapse in patient cohort.
Young people prescribed opioids by dental providers were at increased risk of developing opioid addiction in the following year, a Stanford study found.
An anti-smoking ad campaign featuring a woman with depression helps smokers with mental health conditions attempt to quit.
During a talk at Stanford, journalist and author Barry Meier discussed his nearly two-decade long investigation into OxyContin and Purdue Pharma.
A recent NOVA episode focused on our country's addiction problem and highlighted the work of numerous researchers.
A team of economists have examined the importance of location and opioid prevalence to help tease out the relative importance of supply in the epidemic.
New Stanford research shows alarming trends in teens' use of a popular vaping device, suggesting they need better education about its addictive potential.
Stanford pain specialist argues for comprehensive and personalized treatments as Congress considers legislation to combat the opioid crisis.
Following surgery, the risk of overdose from opioids is highest during the first month. Taking both short- and long-acting opioids also boosts the risk.
Ketamine, a promising new treatment for depression, works through the brain's opioid system, Stanford study finds, defying long held beliefs.